Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial

BACKGROUND: Transmission blocking vaccines targeting the sexual-stages of the malaria parasite could play a major role to achieve elimination and eradication of malaria. The Plasmodium falciparum Pfs25 protein (Pfs25) is the most clinically advanced candidate sexual-stage antigen. IMX313, a compleme...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Front Immunol
Autores principales: de Graaf, Hans, Payne, Ruth O., Taylor, Iona, Miura, Kazutoyo, Long, Carol A., Elias, Sean C., Zaric, Marija, Minassian, Angela M., Silk, Sarah E., Li, Lee, Poulton, Ian D., Baker, Megan, Draper, Simon J., Gbesemete, Diane, Brendish, Nathan J., Martins, Filipa, Marini, Arianna, Mekhaiel, David, Edwards, Nick J., Roberts, Rachel, Vekemans, Johan, Moyle, Sarah, Faust, Saul N., Berrie, Eleanor, Lawrie, Alison M., Hill, Fergal, Hill, Adrian V. S., Biswas, Sumi
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8318801/
https://ncbi.nlm.nih.gov/pubmed/34335606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.694759
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares